Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Enrolls First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Enrollment and Financing of Covid-19 Cohort in Phase III Revival Trial","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Two Presentations at the 27th International Conference on Advances in Critical Care Nephrology","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","amount":"$290.0 million","upfrontCash":"$23.6 million","newsHeadline":"AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"400 Patients Have Been Enrolled in AM-Pharma\u2019s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"},{"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa\u2019s Dual Protective Mechanism","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"AM-Pharma"}]

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism

Details:

Study shows ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury in rodents through the activation of adenosine receptors and the metabolism of extracellular adenosine triphosphate (ATP), a pro-inflammatory molecule.

Lead Product(s): Ilofotase Alfa

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 05, 2022

ASK
US

Upload
your Pipeline Activity

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

400 Patients Have Been Enrolled in AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-associated Acute Kidney Injury

Details:

Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that in multiple clinical trials was shown to be stable and highly active.

Lead Product(s): Ilofotase Alfa

Therapeutic Area: Nephrology Product Name: recAP

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 25, 2022

ASK
US

Upload
your Pipeline Activity

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AM-Pharma Announces Two Presentations at the 27th International Conference on Advances in Critical Care Nephrology

Details:

Ilofotase alfa is a proprietary recombinant alkaline phosphatase, constructed from two human isoforms of alkaline phosphatase, that was shown in multiple clinical trials to be stable and highly active.

Lead Product(s): Ilofotase Alfa

Therapeutic Area: Nephrology Product Name: recAP

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 07, 2022

ASK
US

Upload
your Pipeline Activity

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

Details:

Under the terms of the agreement, AM-Pharma is entitled to tiered double-digit royalties on sales and a drug supply fee. Kyowa Kirin will gain the exclusive right to develop and commercialize ilofotase alfa in Japan.

Lead Product(s): Ilofotase Alfa

Therapeutic Area: Nephrology Product Name: recAP

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Kyowa Kirin

Deal Size: $290.0 million Upfront Cash: $23.6 million

Deal Type: Licensing Agreement September 08, 2021

ASK
US

Upload
your Pipeline Activity

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AM-Pharma Announces Enrollment and Financing of Covid-19 Cohort in Phase III Revival Trial

Details:

The REVIVAL Phase III pivotal trial is a randomized, double-blind, placebo-controlled, two-arm, parallel-group, multi-center trial to evaluate the efficacy and safety of AM-Pharma’s proprietary human recombinant alkaline phosphatase for the treatment of patients with SA-AKI.

Lead Product(s): Ilofotase Alfa

Therapeutic Area: Nephrology Product Name: recAP

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Radboud University Medical Center

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2021

ASK
US

Upload
your Pipeline Activity

AM-Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

AM-Pharma Enrolls First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

Details:

Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study.

Lead Product(s): Ilofotase alfa

Therapeutic Area: Nephrology Product Name: recAP

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Radboud University Medical Center

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 12, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY